Cargando…

Memantine Prevents the WIN 55,212-2 Evoked Cross-Priming of Ethanol-Induced Conditioned Place Preference (CPP)

The activation of the endocannabinoid system controls the release of many neurotransmitters involved in the brain reward pathways, including glutamate. Both endocannabinoid and glutamate systems are crucial for alcohol relapse. In the present study, we hypothesize that N-methyl-D-aspartate (NMDA) gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marszalek-Grabska, Marta, Smaga, Irena, Surowka, Paulina, Grochecki, Pawel, Slowik, Tymoteusz, Filip, Malgorzata, Kotlinska, Jolanta H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348856/ https://www.ncbi.nlm.nih.gov/pubmed/34360704 http://dx.doi.org/10.3390/ijms22157940

Ejemplares similares

Impact of Mephedrone on Fear Memory in Adolescent Rats: Involvement of Matrix Metalloproteinase-9 (MMP-9) and N-Methyl-D-aspartate (NMDA) Receptor
por: Grochecki, Pawel, et al.
Publicado: (2023)

Novel Dopamine Transporter Inhibitor, CE-123, Ameliorates Spatial Memory Deficits Induced by Maternal Separation in Adolescent Rats: Impact of Sex
por: Grochecki, Pawel, et al.
Publicado: (2022)

Alteration of Ethanol Reward by Prior Mephedrone Exposure: The Role of Age and Matrix Metalloproteinase-9 (MMP-9)
por: Grochecki, Pawel, et al.
Publicado: (2022)

WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells
por: Wasik, A M, et al.
Publicado: (2011)

Maternal Separation Alters Ethanol Drinking and Reversal Learning Processes in Adolescent Rats: The Impact of Sex and Glycine Transporter Type 1 (GlyT1) Inhibitor
por: Filarowska-Jurko, Joanna, et al.
Publicado: (2022)

Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain
por: Marchalant, Y, et al.
Publicado: (2009)

Role of Nitric Oxide in the Antipruritic Effect of WIN 55,212-2, a Cannabinoid Agonist
por: Gercek, Oyku Zeynep, et al.
Publicado: (2020)

Cannabinoid WIN55,212-2 reprograms monocytes and macrophages to inhibit LPS-induced inflammation
por: Pérez-Diego, Mario, et al.
Publicado: (2023)

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells
por: Morell, C, et al.
Publicado: (2016)

Gestational exposure to the cannabinoid WIN 55,212-2 and its effect on the innate intestinal immune response
por: Hernández-Cervantes, Rosalía, et al.
Publicado: (2019)

Minimum Alveolar Concentration of Isoflurane in Rats Chronically Treated with the Synthetic Cannabinoid WIN 55,212-2
por: Chavez-Monteagudo, Julio Raul, et al.
Publicado: (2022)

A male mouse model of WIN 55,212–2 self-administration to study cannabinoid addiction
por: Cajiao-Manrique, María del Mar, et al.
Publicado: (2023)

CB(1) receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2
por: Németh, Beáta, et al.
Publicado: (2008)

Microinjection of WIN55,212-2 as A Cannabinoid Agonist into The Basolateral Amygdala Induces Sensitization to Morphine in Rats
por: Molaei, Marzieh, et al.
Publicado: (2014)

Consequences of Adolescent Exposure to the Cannabinoid Receptor Agonist WIN55,212-2 on Working Memory in Female Rats
por: Kirschmann, Erin K., et al.
Publicado: (2017)

Dose-dependent effect of cannabinoid WIN-55,212-2 on myelin repair following a demyelinating insult
por: Tomas-Roig, J., et al.
Publicado: (2020)

PKCε Regulates Behavioral Sensitivity, Binding and Tolerance to the CB1 Receptor Agonist WIN55,212-2
por: Wallace, Melisa J., et al.
Publicado: (2009)

Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2
por: Scholl, Antje, et al.
Publicado: (2016)

The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats
por: Jahanabadi, Samane, et al.
Publicado: (2016)

Cannabinoid WIN 55,212-2 Inhibits Human Glioma Cell Growth by Triggering ROS-Mediated Signal Pathways
por: Wang, Kun, et al.
Publicado: (2021)

Alterations in Rat Accumbens Dopamine, Endocannabinoids and GABA Content During WIN55,212-2 Treatment: The Role of Ghrelin
por: Charalambous, Chrysostomos, et al.
Publicado: (2020)

WIN 55,212-2, Agonist of Cannabinoid Receptors, Prevents Amyloid β(1-42) Effects on Astrocytes in Primary Culture
por: Aguirre-Rueda, Diana, et al.
Publicado: (2015)

WIN55,212-2, a Dual Modulator of Cannabinoid Receptors and G Protein-Coupled Inward Rectifier Potassium Channels
por: An, Dongchen, et al.
Publicado: (2021)

Retracted: Cannabinoid WIN 55,212-2 Inhibits Human Glioma Cell Growth by Triggering ROS-Mediated Signal Pathways
por: International, BioMed Research
Publicado: (2023)

Behavioral and Neurochemical Changes in Mesostriatal Dopaminergic Regions of the Rat after Chronic Administration of the Cannabinoid Receptor Agonist WIN55,212-2
por: Fanarioti, Eleni, et al.
Publicado: (2015)

Sex Differences in the Behavioral and Synaptic Consequences of a Single in vivo Exposure to the Synthetic Cannabimimetic WIN55,212-2 at Puberty and Adulthood
por: Borsoi, Milene, et al.
Publicado: (2019)

Cannabinoid WIN-55,212-2 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1
por: KONG, YING, et al.
Publicado: (2016)

THC exposure during adolescence increases impulsivity-like behavior in adulthood in a WIN 55,212-2 self-administration mouse model
por: Cajiao-Manrique, María del Mar, et al.
Publicado: (2023)

WIN55,212-2-Induced Expression of Mir-29b1 Favours the Suppression of Osteosarcoma Cell Migration in a SPARC-Independent Manner
por: Notaro, Antonietta, et al.
Publicado: (2019)

WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2
por: Aragão, Luiz Guilherme H. S., et al.
Publicado: (2021)

A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats
por: Goonawardena, Anushka V., et al.
Publicado: (2011)

Enhanced self-administration of the CB(1) receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms
por: Amchova, Petra, et al.
Publicado: (2014)

Cannabinoid WIN-55,212-2 mesylate inhibits tumor necrosis factor-α-induced expression of nitric oxide synthase in dorsal root ganglion neurons
por: Tan, Rong, et al.
Publicado: (2018)

The effect of cannabinoid receptor agonist WIN 55,212–2 on anxiety‐like behavior and locomotion in a genetic model of absence seizures in the elevated plus‐maze
por: Cassar, Daniel, et al.
Publicado: (2022)

Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat
por: Vera, Gema, et al.
Publicado: (2023)

WIN55,212-2 Attenuates Cognitive Impairments in AlCl(3) + d-Galactose-Induced Alzheimer’s Disease Rats by Enhancing Neurogenesis and Reversing Oxidative Stress
por: Mahdi, Onesimus, et al.
Publicado: (2021)

Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2
por: Radziszewska, Elżbieta, et al.
Publicado: (2013)

Involvement of the CB(2) cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma
por: Khan, Mohammed I., et al.
Publicado: (2018)

The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB(2), TRPV1, TRPA1 and yet unidentified receptor targets
por: Lowin, Torsten, et al.
Publicado: (2016)

Effects of Mephedrone and Amphetamine Exposure during Adolescence on Spatial Memory in Adulthood: Behavioral and Neurochemical Analysis
por: Grochecki, Pawel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cqt03p9d78aoplnm9vqpafbtiv